Abstract | PURPOSE: METHODS: RESULTS: Median follow-up was 23.5 months (range, one to 50 months). Snellen visual acuity improved by at least two lines in 12 (67%) of 18 patients who were examined after initial injection. Median time to improvement was three weeks. Patients with visual improvement had a median age of 29.0 years, compared with 41.5 years for nonresponders (P = .024). There was a weak association between response to treatment and a history of not smoking (P = .073) after correction for patient age. Increase of intraocular pressure (> 21 mm Hg) occurred in six patients (30%), with onset at a median of three weeks after initial injection; the median interval to peak increase (median, 32 mm Hg; range, 25 to 40 mm Hg) was 14 weeks after the injection. CONCLUSIONS: A subtenon injection of triamcinolone acetonide appears to be an effective treatment for decreased vision associated with intermediate uveitis but may contribute to increase of intraocular pressure in some patients with this disorder.
|
Authors | C J Helm, G N Holland |
Journal | American journal of ophthalmology
(Am J Ophthalmol)
Vol. 120
Issue 1
Pg. 55-64
(Jul 1995)
ISSN: 0002-9394 [Print] United States |
PMID | 7611330
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Fascia
(drug effects)
- Female
- Follow-Up Studies
- Humans
- Injections
- Intraocular Pressure
(drug effects)
- Male
- Middle Aged
- Ocular Hypertension
(chemically induced)
- Orbit
(drug effects)
- Postoperative Complications
- Triamcinolone Acetonide
(administration & dosage, adverse effects, therapeutic use)
- Uveitis, Intermediate
(drug therapy)
- Vision Disorders
(drug therapy)
- Visual Acuity
|